Objective: To explore the potential of autologous dendritic cells (DCs) pulsed with caner/testis antigen NY-ESO-1 peptides in inducing specific cytotoxic T lymphocyte (CTLs) response and antineoplastic immune function of specific CTLs. Methods: Fifteen patients with Ⅱ to Ⅲ stage positive HLA-A0201+ and NY-ESO-1+ were enrolled in the Cancer Hospital Chinese Academy of Medical Sciences on the basis of preclinical experiments from November 2014 to October 2015, and their peripheral blood mononuclear cells (PBMCs) and peripheral blood lymphocytes (PBLs) were isolated. The PBMCs were induced into DCs and pulsed with NY-ESO-1 peptide. The phenotypes of DCs were stained with antibodies against HLA-DR+CD11c+,CD80+,CD83+ and CD86+, and subsequently analyzed by multichannel flow cytometry (FCM). The killing effects of CTLs pulsed with HLA-A0201-binding peptide NY-ESO-1 and the potential of autologous DCs pulsed with NY-ESO-1 peptides in inducing specific cytotoxic T lymphocytes (CTLs) responses were determined. The patients were administered two infusions of auto-logous CTLs for 1 time every two weeks. The total infusion was with 2 times. The immunological responses and clinical responses were examined in 1 week after the final administration. Results: The immunophenotype of DCs pulsed with NY-ESO-1 peptide was analyzed, HLA-DR+CD11c+ cells (93.6%±1.2%), CD80+ cells (87.3%±3.6%), CD83+ cells (82.8%±2.5%) and CD86+ cells (93.4%±6.4%). PBLs isolated from patients primed by DCs pulsed with NY-ESO-1 peptide proliferated continuously and the proliferation index (PI) of the PBLs were analyzed. There was significant difference between the DCs loaded with polypeptides and those unloaded, though it could promote the proliferation of PBLs, but the PI was significantly lower than that of the DCs loaded with NY-ESO-1 peptide (P<0.05). The average percentage of special CTLs primed by DCs pulsed with NY-ESO-1 peptides was significantly higher than that in the control group (5.2%±1.2% vs. 0.4%±0.1%). CTLs induced by NY-ESO-1 pulsed DCs exerted a stronger killing effect on T2 cell line pulsed with NY-ESO-1 peptide than that in the control group at the ratio of E (effect) to T (target) as 30︰1, P<0.05. The cytokine levels in the patients’sera such as IFN-γ, IL-2 and IL-12 were increased after treatments [(132.9±10.2) μg/L vs. (46.4±3.1) μg/L; (101.3±6.4) μg/L vs. (26.7±1.2) μg/L; (51.3±2.6) μg/L vs. (26.4±1.1) μg/L; all P<0.05], and the percentages of antigen-specific CD8+IFN-γ+ increased in these patients (P<0.01). Conclusion:Auto-DCs pulsed with NY-ESO-1 peptides can induce the proliferation of allogenic CTLs, which elicit specific immune responses ex vivo or in vivo, and boost anticancer immunity markedly.
LIU Jing-wei
,
LU Xu
,
YANG Zhao-min
,
DENG Li-juan
,
YANG Lin
. Immune effects of specific CTLs response induced by dendritic cells pulsed with NY-ESO-1 peptide[J]. Journal of Peking University(Health Sciences), 2017
, 49(5)
: 840
-846
.
DOI: 10.3969/j.issn.1671-167X.2017.05.017
[1] Varadhachary G, Ajani JA. Gastric cancer[J].Clin Adv Hematol Oncol, 2005, 3(2): 118-124.
[2] Ajani JA.Evolving chemotherapy for advanced gastric cancer[J].Oncologist, 2005, 10(3): 49-58.
[3] Yoshihara M, Hiyama T, Yoshida S, et al.Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case-control study[J].Scand J Gastroenterol, 2007, 42(6): 760-764.
[4] Larmonier N, Fraszczak J, Lakomy D, et a1.Killer dendritic cells and their potential for cancer immunotherapy[J].Cancer Immunol Immunother, 2010, 59(1): 1-11.
[5] Rosenberg SA, Restifo NP, Yang JC, et a1. Adoptive cell transfer:a clinical path to effective cancer immunotherapy[J]. Nat Rev Cancer, 2008, 8(4): 299-308.
[6] Gnjatic S, Atanackovic D, Jager E, et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses [J] . Proc Natl Acad Sci USA, 2003, 100(15): 8862-8867.
[7] Simone K, Cristina B, Judith F, et al. Rapid generation of NY-ESO-1-specific CD4 + T HELPER 1 cells for adoptive T-cell therapy [J]. OncoImmunology, 2015, 4(5): e1002723.
[8] Park TS, Groh EM, Patel K, et al. Expression of MAGE-A and NY-ESO-1 in primary and metastatic cancers[J].J Immunother, 2016, 39(1): 1-7.
[9] Scanlan M J, Altorki NK, Gure AO, et al. Expression of cancer-testis antigens in lung cancer: definition of bromodoma in testis-specific gene (BRDT) as a new CT gene, CT9 [J]. Cancer Lett, 2000, 150(2): 155-164.
[10] Luo G, Huang S, Xie X, et al. Expression of cancer-testis genes in human hepatocellular carcinomas [J] . Cancer Immun, 2002, 19(2): 11.
[11] Ghafouri-Fard S, Shamsi R, Seifi-Alan M, et al. Cancer-testis genes as candidates for immunotherapy in breast cancer[J]. Immunotherapy, 2014, 6(2): 165-179.
[12] Lee HJ, Kim JY, Song IH, et al. Expression of NY-ESO-1 in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and a good prognosis[J]. Oncology, 2015, 89(6): 337-344.
[13] Mashino K, Sadanaga N, Tanaka F, et al. Expression of multiple cancer-test is antigen genes in gastrointestinal and breast carcinomas [J]. Br J Cancer, 2001, 85(5): 713-720.
[14] Galluzzi L, Senovilla L, Vacchelli E, et al. Trial watch: dendritic cell-based interventions for cancer therapy [J]. Oncoimmunology, 2012, 2(10): 1111-1134.
[15] Paezesny S, Sift FI, Saito H, et a1.Measuring melanoma-specific cytotoxic T lymphocytes elicited by dendritic cell vaccine with a tumor inhibition assay in vitro [J].J lmmunolher, 2005, 28(2): 148-157.
[16] Shi H, Cao T, Connolly JE, et al. Hyperthermia enhances CTL cross-priming [J]. J Immunol, 2006, 176(4): 2134-2141.
[17] 虞淦军, 万涛. NY-ESO-1 抗原的基础与临床研究进展[J].中国肿瘤生物治疗杂志, 2015, 22(1): 104-111.
[18] 陈军, 尚小云, 唐波, 等. 胃癌、食管癌中NY-ESO-1抗原特异性免疫应答与生存率的关系研究[J]. 第三军医大学学报, 2009, 31(10): 984-986.
[19] 吴晓江, 王俞欠, 季加孚,等.胃癌中肿瘤/睾丸抗原的表达研究及NY-ESO-1蛋白的自身抗体检测[J]. 北京大学学报(医学版), 2005, 37(3): 252-256.
[20] Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma [J]. Nat Med, 2015, 21(8): 914-921.
[21] Robbins PF, Li YF, El-Gamil M, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions [J]. J Immunol, 2008, 180(9): 6116-6131.
[22] Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8 + T cell dysfunction in melanoma patients[J]. J Exp Med, 2010, 207(10): 2175-2186.
[23] Zitvogel L, Galluzzi L, Smyth MJ, et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance [J]. Immunity, 2013, 39(1): 74-88.
